Adc Therapeutics SA’s recent filing unveils that its 10% Owner Redmile Group, LLC acquired Company’s shares for reported $1.12 million on Jul 01 ’24. In the deal valued at $2.81 per share,400,000 shares were bought. As a result of this transaction, Redmile Group, LLC now holds 15,669,217 shares worth roughly $48.26 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Redmile Group, LLC bought 400,000 shares, generating $1,124,000 in total proceeds. Upon buying the shares at $2.81, the 10% Owner now owns 12,995,040 shares.
Before that, Azelby Robert sold 6,995 shares. Adc Therapeutics SA shares valued at $20,216 were divested by the Director at a price of $2.89 per share. As a result of the transaction, Azelby Robert now holds 53,005 shares, worth roughly $0.16 million.
Cantor Fitzgerald initiated its Adc Therapeutics SA [ADCT] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. JP Morgan also remained covering ADCT and has increased its forecast on August 10, 2023 with a “Neutral” recommendation from previously “an Underweight” rating. BofA Securities revised its rating on April 24, 2023. It rated ADCT as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of ADCT
On Friday, Adc Therapeutics SA [NYSE:ADCT] saw its stock jump 12.41% to $3.08. Over the last five days, the stock has lost -6.38%. Adc Therapeutics SA shares have risen nearly 85.54% since the year began. Nevertheless, the stocks have risen 280.25% over the past one year. While a 52-week high of $6.04 was reached on 02/20/24, a 52-week low of $0.36 was recorded on 01/04/24. SMA at 50 days reached $2.96, while 200 days put it at $3.55.
Levels Of Support And Resistance For ADCT Stock
The 24-hour chart illustrates a support level at 2.83, which if violated will result in even more drops to 2.57. On the upside, there is a resistance level at 3.21. A further resistance level may holdings at 3.33. The Relative Strength Index (RSI) on the 14-day chart is 51.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 49.33%. Stochastics %K at 28.54% indicates the stock is a holding.
How much short interest is there in Adc Therapeutics SA?
A steep rise in short interest was recorded in Adc Therapeutics SA stocks on 2024-09-30, growing by 0.84 million shares to a total of 3.56 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 2.71 million shares. There was a rise of 23.71%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 06, 2022 when CapitalOne began covering the stock and recommended ‘”an Overweight”‘ rating along with a $12 price target.
